Peptimmune wins new patent for peptide copolymer

Peptimmune’s PI-2301 is currently in a Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study in subjects with multiple sclerosis.

Following establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the company plans to initiate its Phase II study in relapsing remitting multiple sclerosis patients in early 2009.

Thomas Mathers, president and CEO of Peptimmune, said: “This patent represents an important component in the development of our intellectual property in peptide copolymers, including PI-2301. The patent protects what we believe may become a very important therapy for the treatment of multiple sclerosis and other autoimmune diseases.”